Boill Healthcare Swings to Massive HK$873 Million Annual Loss on Property Write-Downs and Credit Charges

Boill Healthcare Holdings Limited ( (HK:1246) ) has provided an update.

Boill Healthcare Holdings Limited reported a sharp deterioration in its financial performance for the year ended 31 March 2025, with revenue plunging to HK$76.9 million from HK$285.2 million a year earlier and the group swinging to a gross loss of HK$7.0 million from a gross profit of HK$11.7 million. The company posted a net loss of HK$872.9 million, significantly wider than the HK$283.1 million loss in the previous year, driven by substantial fair value losses on investment properties of HK$449.2 million, a HK$299.5 million provision for properties under development, and higher expected credit losses on financial guarantee contracts and receivables. Finance costs more than tripled to HK$66.2 million, while total comprehensive loss narrowed slightly to HK$864.9 million due to foreign exchange gains, but loss attributable to shareholders surged to HK$830.0 million, translating into a basic and diluted loss per share of HK61.12 cents versus HK8.74 cents a year earlier. The results underscore escalating pressure on the group’s property and healthcare-focused assets and balance sheet, pointing to continued challenges in monetising its portfolio and managing credit and valuation risks for stakeholders.

More about Boill Healthcare Holdings Limited

Boill Healthcare Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the healthcare-related property and services sector, with activities including property development, investment properties and healthcare-focused real estate projects. The group generates revenue primarily from sales of properties and related services in mainland China and Hong Kong, positioning itself within the broader healthcare and property markets.

Technical Sentiment Signal: Sell

Current Market Cap: HK$28.52M

Learn more about 1246 stock on TipRanks’ Stock Analysis page.